CA3048771C - Formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazol o[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate - Google Patents

Formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazol o[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate

Info

Publication number
CA3048771C
CA3048771C CA3048771A CA3048771A CA3048771C CA 3048771 C CA3048771 C CA 3048771C CA 3048771 A CA3048771 A CA 3048771A CA 3048771 A CA3048771 A CA 3048771A CA 3048771 C CA3048771 C CA 3048771C
Authority
CA
Canada
Prior art keywords
compound
xrpd
solid form
solid
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3048771A
Other languages
English (en)
Other versions
CA3048771A1 (fr
Inventor
Katja GROSSE-SENDER
Urs Schwitter
Frank Stowasser
Xuemei Wang
Jing Xiong
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority claimed from PCT/EP2018/050160 external-priority patent/WO2018127526A2/fr
Publication of CA3048771A1 publication Critical patent/CA3048771A1/fr
Application granted granted Critical
Publication of CA3048771C publication Critical patent/CA3048771C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne de nouvelles formes solides du composé (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tétrahydrofuran-2-yl]propyl] acétate et des compositions pharmaceutiques comprenant lesdites formes solides, qui peuvent être utilisées en tant qu'agoniste TLR7, ou pour le traitement ou la prophylaxie d'une maladie virale chez un patient associée à une infection par le VHB ou une maladie provoquée par l'infection par le VHB.
CA3048771A 2017-01-06 2018-01-04 Formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazol o[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate Active CA3048771C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017070439 2017-01-06
CNPCT/CN2017/070439 2017-01-06
CNPCT/CN2017/092183 2017-07-07
CN2017092183 2017-07-07
CN2017112151 2017-11-21
CNPCT/CN2017/112151 2017-11-21
PCT/EP2018/050160 WO2018127526A2 (fr) 2017-01-06 2018-01-04 Nouvelles formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tétrahydrofuran-2-yl]propyl] acétate

Publications (2)

Publication Number Publication Date
CA3048771A1 CA3048771A1 (fr) 2018-07-12
CA3048771C true CA3048771C (fr) 2025-12-30

Family

ID=

Similar Documents

Publication Publication Date Title
JP7199739B2 (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
EP3322704B1 (fr) Forme crystalline de la 4-quinazolinamine n-[(3-amino-3-oxétanyl)méthyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazépin-4(5h)-yl)-6-méthyl pour le traitement des infections par le virus respiratoire syncytial (vrs)
CN110891947B (zh) 制备艾乐替尼或其药学上可接受的盐的方法
US12012421B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
KR20230170921A (ko) 퀴놀린 유도체 화합물의 제조 방법
CA3048771C (fr) Formes solides de [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazol o[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
JP2012527417A (ja) ｛［（２ｓ，５ｒ，８ｓ，１１ｓ）−５−ベンジル−１１−（３−グアニジノ−プロピル）−８−イソプロピル−７−メチル−３，６，９，１２，１５−ペンタオキソ−１，４，７，１０，１３−ペンタアザ−シクロペンタデカ−２−イル］−酢酸｝の新規な固体物質およびそれらを得るための方法
WO2018042320A1 (fr) Sels de betrixaban et leurs procédés de préparation
HK40012489B (en) Solid forms of [(1 s)-1 -[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
HK40012489A (en) Solid forms of [(1 s)-1 -[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
CN102341392A (zh) 二氢苯并噁唑-6-基-乙酰胺衍生物的新的结晶水合物、无定形和多晶型形式及其制备方法
BR112019013911B1 (pt) Novas formas sólidas de acetato de [(1s)-1-[2s,4r,5r)-5-(5-amino-2-oxotiazolo[ 4,5-d]pirimidin-3-il)-4-hidroxi-tetrahidrofuran-2il]propil
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib